- Successor Expected to be Announced Shortly -
WALTHAM, Mass.--(BUSINESS WIRE)--
Inc. (Nasdaq: IMGN) a biotechnology company that develops targeted
anticancer therapeutics using its antibody-drug conjugate (ADC)
technology, today announced that Daniel Junius, age 63, has decided to
retire from his positions of President and CEO of the Company. This will
become effective when his successor joins ImmunoGen. Mr. Junius has been
the Company's CEO since January 2009. Following his retirement, Mr.
Junius will continue to serve on ImmunoGen's Board of Directors.
In September 2015, Mr. Junius discussed with ImmunoGen's Board that he
was considering retiring by the end of the Company's fiscal year in June
if an appropriate successor could be found within that timeframe. The
Board then formed a search committee, retained an executive recruitment
firm, and began formal succession planning. It is currently anticipated
that a successor to Mr. Junius will be announced shortly.
"Dan has taken ImmunoGen from being a research company with a validated
technology to one with strong research, development, clinical and
manufacturing functions that is advancing a rich pipeline of product
candidates driven by an expanding technology portfolio," commented
Stephen McCluski, Chairman of the Board. "The Board is grateful to Dan
for his extensive contributions to ImmunoGen and his commitment to
making a difference for patients with cancer."
"For over seven years, I have had the privilege of leading a company
full of smart, team-oriented employees committed to developing better
treatments for cancer," noted Mr. Junius. "I believe ImmunoGen is in a
strong position today and look forward to its continued advancement
under the next CEO."
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that develops
targeted anticancer therapeutics using its proprietary ADC technology.
The Company's lead product candidate, mirvetuximab soravtansine, is in
Phase 2 testing for the treatment of folate receptor α-positive ovarian
cancer. ImmunoGen's ADC technology is used in Roche's marketed product,
Kadcyla®, and in programs in development by partners Amgen,
Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More
information about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of
the Roche Group.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160405005301/en/
Carol Hausner, 781-895-0600
Michael Lampe, 484-575-5040
Source: ImmunoGen, Inc.
News Provided by Acquire Media